

# Lin28 and *let-7* in cell metabolism and cancer

Liem H. Nguyen, Hao Zhu

Children's Research Institute, Departments of Pediatrics and Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

Correspondence to: Hao Zhu, Children's Research Institute, Departments of Pediatrics and Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Email: hao.zhu@utsouthwestern.edu.

**Abstract:** Malignant cells exhibit major metabolic alterations. The regulatory gene networks that regulate metabolism and the impact of these alterations on overall cellular fitness deserve further exploration. The *let-7* microRNAs and their antagonists, the Lin28 RNA-binding proteins, are well-known for controlling the timing of embryonic development. This pathway has recently been shown to regulate glucose metabolism in adult mice and to reprogram metabolism during tissue injury and repair. In addition, many lines of evidence have established that *Lin28* is an oncogene that drives tumorigenesis in part by suppressing *let-7*. The metabolic underpinnings of this oncogenic program are just beginning to be uncovered. Here, we will review the current understanding of how Lin28 exerts regenerative and oncogenic effects through metabolic mechanisms.

**Keywords:** *Lin28*, *let-7*; cancer; regeneration; metabolism

Submitted Jan 12, 2015. Accepted for publication Jan 22, 2015.

doi: 10.3978/j.issn.2224-4336.2015.01.05

View this article at: <http://dx.doi.org/10.3978/j.issn.2224-4336.2015.01.05>

## Introduction

Metabolism governs cellular homeostasis, growth, and survival. Alterations in cell metabolism are a common feature of cancer and have been increasingly viewed as one of the hallmarks of malignant transformation (1). In order to support their high proliferative rates, cancer cells adapt to their environment in part by reprogramming the metabolism of all major classes of macromolecules: proteins, carbohydrates, nucleic acids, and lipids (1). This link between metabolism and cancer is not a novel observation. Sixty years ago, Otto Warburg first noted that under normoxic conditions, normal cells metabolize glucose by using mitochondrial oxidative phosphorylation (OxPhos) instead of glycolysis to maximize the production of adenosine triphosphate (ATP), while some cancer cells rely more on aerobic glycolysis, a phenomenon later known as the Warburg effect (2). Since then, interest in this topic has increased and major areas of knowledge have been gained, but fundamentally important questions remain unresolved. The upstream signals that trigger metabolic alterations in cancer cells and what impact these changes have on overall tumor development and progression are still under

intense investigation.

Many of the signaling pathways altered in oncogenesis, such as the PI3K-Akt-mTOR pathway (3), can reprogram cell metabolism in a way that promotes malignant growth (1,4). Recently, *Lin28a* and its homolog *Lin28b* (collectively referred to as *Lin28*) and the *let-7* microRNA family, have been found to play a direct role in regulating glucose metabolism in adult tissues (5-8). In addition, mouse genetic studies have shown that the reactivation of *Lin28* can drive tumor initiation and progression through *let-7* dependent and independent mechanisms (9-13). Although all the connections have not been made, it is possible that reprogramming cell metabolism could be a major mechanism by which Lin28 exerts its oncogenic effects. Determining how Lin28 regulates metabolic reprogramming may provide an additional way to understand the interplay between oncogenic signaling pathways and cellular metabolism. We will first summarize roles for Lin28 and *let-7* in regulating self-renewal and differentiation in stem cells and cancer. Then, we will discuss their roles in regulating metabolism.

## The *Lin28/let-7* axis temporally regulates self-renewal and differentiation

*Lin28* and *let-7* were first identified through mutagenesis screens as heterochronic genes that govern developmental timing in *C. elegans* (14-17). *Lin28* homologs are RNA-binding proteins that consist of zinc fingers (consisting of cysteine and histidine residues in the order CCHC) zinc fingers and cold shock RNA binding domains (16). Subsequent genetic loss and gain-of-function studies in worms revealed that *Lin28* promotes self-renewal and delays differentiation of the hypodermal and vulval progenitor cells (16). As expected from these functions, *Lin28* expression is high during embryogenesis and early larval stage of development, and gradually declines to an undetectable level in adult tissues (18). In contrast, *let-7* expression increases as *Lin28* expression wanes from late larval stage and remains high thereafter (14,19). Loss-of-function *let-7* mutations promote the division of seam cells and prevent them from cell cycle exit (20), phenocopying *Lin28* gain-of-function mutants (19). Later, it was shown that *let-7* promotes differentiation and inhibits self-renewal during the transition from larva to adulthood by repressing *Lin28* expression through its 3'UTR (16,18).

The expression and regulation of *Lin28* and *let-7* are highly conserved throughout evolution (18). In mice, *Lin28* is expressed at high levels throughout the embryo at early developmental stages (~E6.5) (21). Then, its expression declines through development and remains present in only some adult tissues (21). Whether *Lin28* also functions to promote stemness in mammals became more intriguing when overexpressing *Lin28a*, along with *Sox2*, *Oct4*, and *Nanog*, proved to be sufficient to reprogram human somatic fibroblasts into inducible Pluripotent Stem Cells (iPSCs) (22). Nevertheless, the mechanism by which *Lin28* exerted this effect remained a mystery until a flurry of studies showed that in both mouse embryonic stem cells (ESCs) and *C. elegans* epithelial stem cells, *Lin28* inhibits the post-transcriptional maturation of *let-7*. *Lin28* binds to the primary immature form of *let-7* and sequesters it from being processed by *Drosha/DGCR8* (the small RNA generating machinery in the nucleus) (23,24). In the cytoplasm, *Lin28* blocks the loading of *let-7* into *Dicer* by binding the premature form of *let-7* and recruiting *Tutase4/7*, which polyuridylylates *let-7*'s tail, marking it for degradation by an exonuclease called *Dis3l2* (24-35). Thus, when antagonized by *Lin28*, *let-7* is rendered inactive.

Studies in mouse ESCs also demonstrated that *let-7*

antagonizes self-renewal and promotes differentiation. Melton *et al.* showed that *Drosha/DGCR8* knockout ESCs, which are unable to produce most mature miRNAs, fail to silence the stem cell self-renewal program when placed under differentiation-inducing conditions. Introduction of mature *let-7* into these *Drosha/DGCR8* knockout ESCs is capable of rescuing differentiation and even inhibits ESC self-renewal in stem cell culture conditions (36). These phenotypes were in part due to the *let-7* mediated suppression of pluripotency factors such as *Lin28*, *Sal4*, and *N-Myc* (36). More recently, Worringer *et al.* in Yamanaka's group showed that *let-7* acts as a barrier to counteract iPSC reprogramming by promoting the expression of differentiation genes (37). Thus, together *Lin28* and *let-7* form a highly conserved and highly regulated axis that temporally regulates the self-renewal and differentiation of stem cells.

## *Lin28a* and *Lin28b* are oncogenes

In adult mammalian tissues, *let-7* is one of the most abundant miRNAs (38). Although the exact roles of *let-7* in adult tissues have not been fully characterized, *let-7* is known to have tumor suppressor functions. There is copious evidence that *let-7* expression is downregulated in a large number of cancers (39-43) and that *let-7* overexpression inhibits growth and transformation of cancer cell lines and tumor xenografts (44-52). These anti-cancer effects are partly due to the suppression of *let-7* target genes that are critical for cell cycle progression and proliferation, such as *K-Ras*, *Cyclin D1*, *c-Myc*, *Cdc34*, *Hmga2*, *E2f2*, and *Lin28* (45-49,51,53). Most of these findings were discovered in cell lines, and thus our knowledge of *let-7* functions would benefit from more definitive investigation in animal models.

In contrast to *let-7*, *Lin28* expression is upregulated in multiple tumor types such as neuroblastoma, hepatocellular carcinoma (HCC), Wilms' tumor, and melanoma (13). Several studies have demonstrated that activation of *Lin28* is able to promote tumor development in various mouse tissues in part by suppressing *let-7* (9-12). Furthermore, we recently showed that genetic deletion of *Lin28a* and *Lin28b* abrogated *c-MYC*-driven hepatocarcinogenesis and improved overall survival in mice (12). Similar results were achieved using *in vivo* siRNA to knockdown *Lin28b*, which resulted in greater levels of cell death in tumor tissues (12). In another study, He *et al.* isolated pre-malignant liver progenitor cells from Diethylnitrosamine mutagenized mice and

showed that these cells have high expression of *Lin28a* and *Lin28b*, suggesting that Lin28 plays a role in malignant transformation within the chronically injured liver (54). These studies have functionally established the role of *Lin28* in tumor initiation and progression and suggest that Lin28 could be a relevant target for either cancer prevention or therapy.

Although many major effects of Lin28 are mediated through *let-7*, Lin28 can also directly bind to and influence the translation of many mRNAs enriched with GGAGA (with G = guanosine and A = adenosine) sequences in their loop structures (55). Many of these mRNAs are oncogenic or growth-promoting genes, such as *Igf2*, *Igf2-mRNA* binding proteins, *Hmga1*, or those encoding ribosomal proteins, cell-cycle regulators, and metabolic enzymes (6, 12,55-59). Whether or not and to what extent these mRNA targets of Lin28 contribute to its oncogenic effects are important areas for future investigation.

### The *Lin28/let-7* axis regulates metabolism in mammalian ESCs

Studies in mammalian ESCs provided initial insights into the role of the *Lin28/let-7* axis in metabolism. Genome-wide studies in human ESCs revealed that Lin28 binds to many mitochondrial enzyme mRNAs and interacts with RNA helicase A to enhance the translation of these mRNAs (56). In mouse ESCs, Wang *et al.* recently showed that threonine (Thr) oxidation into glycine (Gly) and acetyl-CoA catalyzed by threonine dehydrogenase is critical for cell growth (60). A follow-up study by Shyh-Chang *et al.* revealed that the catabolism of Thr also fuels the synthesis of S-adenosyl-methionine (SAM), which is important for methylation reactions and critical for pluripotency (61). Decreased SAM ultimately led to slowed growth and increased differentiation (61). Metabolic profiling also demonstrated that inducing *Lin28* and *let-7* had dramatic effects on the Thr-Gly-SAM pathway in mouse ESCs (61). Specifically, overexpressing *Lin28* in mouse ESCs led to increased amount of many Thr-Gly-SAM metabolites, while overexpressing *let-7* led to reduced amount of these metabolites (61). Together, these studies provided the first evidence that the *Lin28/let-7* axis regulates metabolic networks in ESCs.


### Lin28 regulates body size, metabolism, and tissue regeneration in adult mice

Lin28 and *let-7* also modulate the expression of pathways

that directly regulate metabolism in adult mammalian tissues. For gain of function studies, we previously engineered a tetracycline-inducible *Lin28a* transgenic mouse model [*Lin28a* transgenic (Tg)]. Due to leakiness of the transgene, *Lin28a* expression levels are modestly increased in the muscle, skin and connective tissues in the absence of doxycycline induction. We reported that *Lin28a* Tg mice, compared to control mice without the transgene, exhibited increased body size and delayed puberty onset (62). These phenotypes functionally validated a number of genome-wide association studies that identified connections between human height, puberty timing, and the *LIN28B* locus (63,64).

Most interestingly, *Lin28a* Tg mice exhibit enhanced glucose uptake in peripheral tissues (62). Enhanced glucose uptake in *Lin28a* Tg mice also led to higher levels of the glycolytic metabolite lactate (62). Similarly, whole body inducible human *LIN28B* overexpressing mice also exhibit superior glucose tolerance, indicating conserved functions between the *Lin28* paralogs from two species (6). While gain-of-function *Lin28a* results in increased body size, loss-of-function *Lin28a* [*Lin28a* knockout (KO)] caused dwarfism from E13.5 to adulthood (65). Conditional deletion of *Lin28a* in skeletal muscles led to insulin resistance and impaired glucose uptake, indicating that *Lin28* is physiologically required for normal glucose homeostasis (6,65). In contrast to the phenotypes seen in *Lin28a* Tg mice, inducible *let-7* Tg mice not only have reduced body size and growth retardation, but also have hyperglycemia and glucose intolerance (6). Simultaneous *Lin28a* and *let-7* whole body overexpression cancels out the glucose phenotype of each factor. Thus, there are likely to be mutually antagonistic effects including the possibility that Lin28a increases glucose uptake by suppressing *let-7* (6) (Figure 1A).

Mechanistically, the overgrowth of *Lin28a* Tg mice could partly be due to the reduction of *let-7* expression levels in organs where endogenous *Lin28a* is not normally present (62) and global increases in *let-7*-target protein production, such as *Hmga1*, *Igf2*, and *Oct4*—all of which are known to regulate body size (6,66-68). To further illustrate that the enhanced glucose uptake seen in *Lin28a* Tg mice was due to cell autonomous mechanisms, *Lin28a* was overexpressed in C2C12 myoblasts. Compared to control myoblasts, *Lin28a* overexpressing myoblasts take up glucose much faster (Figure 1A). This was the result of Lin28a suppressing *let-7*, which in turn suppresses the Insulin-PI3K-mTOR pathway at multiple nodes (namely, Igf1r, Insulin receptor,



**Figure 1** Reactivation of *Lin28* reprograms cell metabolism to enhance tissue regeneration and promote cancer growth. (A) Reactivation of *Lin28* in physiological condition in mouse tissues enhances regeneration by suppressing *let-7*, upregulating *K-Ras* expression and the insulin-PI3K-mTOR signaling, and more importantly upregulating the expression of metabolic machinery. These changes lead to enhanced glucose uptake, increased activity of both glycolysis and OxPhos, resulting in *Lin28*-positive cells having a much higher bioenergetic state; (B) Reactivation of *Lin28* promotes growth of multiple cancer cell lines in part by suppressing *let-7* and upregulating PDK1 protein expression. When *let-7* expression is reduced, glucose uptake is enhanced. PDK1 is a negative regulator of OxPhos activity since it inhibits the conversion of pyruvate to acetyl-CoA. When PDK1 expression is enhanced by *Lin28* overexpression and *let-7* suppression, it promotes glycolysis and blocks OxPhos activity. Consequently, *Lin28*-positive cancer cells switch to aerobic glycolysis for glucose metabolism.

and *Irs2*) (Figure 1A). In terms of signaling output, Akt and S6 phosphorylation is increased in a *let-7*-dependent manner, which increases the insulin-sensitivity and glucose uptake of myoblasts (6). Furthermore, when muscle specific *Tsc1* deficient mice, whose mTOR signaling is increased, were crossed with *Lin28b* deficient mice, *Lin28b*'s dwarfism phenotype was rescued. This further confirmed that mTOR signaling genetically interacts with the *Lin28* program (65). Another line of evidence that further corroborates this concept is a recent report showing that under nutrient deprivation, *let-7* prevents mTORC1 activation to induce autophagy in primary cortical neurons, muscle, and white fat (69). These studies show that the *Lin28/let-7* axis strongly influences a known controller of organismal and

cancer metabolism, but the following studies demonstrated more interesting mechanisms.

Overexpressing just a modest amount of *Lin28a* led to increased body size and delayed mouse puberty (62). Even more striking is the superior tissue repair observed in *Lin28a* Tg mice (7). We and the Daley Lab showed that *Lin28a* Tg mice exhibited enhanced hair regeneration after shaving, digit repair after amputation, and ear wound healing after hole punch (7). We found that this superior regenerative phenotype in *Lin28a* Tg mice was not caused by suppression of *let-7* alone, since *let-7* antimir delivered to wild-type (WT) mice failed to phenocopy the enhanced regeneration caused by *Lin28a* overexpression (7). By profiling metabolism during tissue repair, we demonstrated



that Lin28a enhances both glycolysis and mitochondrial OxPhos activity through direct binding and translational enhancement of mRNAs that encode several major metabolic enzymes such as phosphofructokinase, pyruvate dehydrogenase (PDH), and isocitrate dehydrogenase (7) (Figure 1A). However, enhancement of OxPhos activity by Lin28a turned out to be required for better regeneration in all examined tissues, whereas enhancement of glycolysis was only required in some contexts (Figure 1A). To further understand how this metabolic enhancement influences tissue regeneration, Shyh-Chang *et al.* treated *Lin28a* Tg mouse embryonic fibroblasts (MEFs), which migrate significantly faster than WT MEFs, with an OxPhos inhibitor and found that the pro-migration phenotype was preferentially suppressed in *Lin28a* overexpressing cells (7). This suggested that *Lin28a*-mediated metabolic enhancements are sufficient to promote cell migration (7). Consistent with the fact that suppression of *let-7* alone was not sufficient to recapitulate the regenerative phenotype, suppression of *let-7* in MEFs had no effect on cell migration (7). Taken together, these lines of evidence demonstrated that Lin28 regulates metabolism through direct impact on the translation of core metabolic enzymes.

### Metabolic reprogramming by the *Lin28/let-7* axis in cancer

Recent evidence shows that these oncogenic effects have a metabolic basis. Ma *et al.* showed that overexpression of either *LIN28A* or *LIN28B* in Hep3B, a human liver cancer cell line, promotes the Warburg effect in the form of enhanced glucose uptake, lactate production, and O<sub>2</sub> consumption rate (70) (Figure 1B). Treating these cells with *let-7* mimics, however, resulted in the opposite effects (70) (Figure 1B). Unexpectedly, they found that *LIN28*-overexpressing cell lines under normoxic condition showed only marginally activated AKT-mTOR signaling when *LIN28A* or *LIN28B* is expressed (70). However, when they examined protein expression of metabolic enzymes, they found that PDH kinase 1 (PDK1) was highly upregulated in multiple *LIN28*-overexpressing cancer cell lines (70) (Figure 1B). PDK1 is a well-known metabolic regulator whose role is to inhibit the conversion of pyruvate to acetyl-CoA, which is used as a starting material for the Krebs cycle. PDK1 does so by phosphorylating PDH and inhibiting its activity (71) (Figure 1B).

The regulation of PDK1 by LIN28 most likely occurs post-transcriptionally since the *PDK1* mRNA level was

unchanged (70). Consistent with the fact that *let-7* mimics block glucose uptake in the examined cancer cell lines, *let-7* was shown to specifically suppress *PDK1* expression but no other OxPhos enzymes (70). Luciferase experiments with *PDK1* 3' UTR demonstrated that *PDK1* is a direct target of *let-7* (70) (Figure 1B). More importantly, Ma *et al.* showed that knocking down *PDK1* in cell lines and xenografts impaired the growth-promoting effects of *LIN28* overexpression (70). Together, this study made two important findings: first, when expressed in multiple cancer cell lines, Lin28 actively promotes aerobic glycolysis while inhibiting mitochondrial OxPhos, distinct from what we reported in the context of tissue repair. Second, blocking a metabolic effector of the *Lin28* program in this context can disrupt cancer cell growth. Recently, we also showed that conditionally overexpressing human *LIN28B* in the liver resulted in the development of liver cancer, with histological features of both hepatoblastoma and HCC (12). Based on 2-deoxy-2-(<sup>18</sup>F) fluoro-D-glucose positron emission tomography imaging, human *LIN28B*-driven liver tumors are more glucose-avid than surrounding normal tissues, a feature that is seen only in a subset of aggressive human HCC (12). In light of the Lin28 and PDK1 connection, it would be interesting to determine if LIN28B preferentially promotes aerobic glycolysis in this endogenous cancer setting, and what role this metabolic mechanism has on tumor initiation and progression. If inhibition of aerobic glycolysis or glycolytic enzymes such as PDK1 can abrogate the oncogenic effects of LIN28B, it would not only support the idea that Lin28 promotes aerobic glycolysis, but also identifies a downstream effector of the *Lin28* program that is potentially druggable. As molecules that effectively block Lin28 activity have not yet been developed, identifying a more readily actionable target could be beneficial in treating *Lin28*-expressing cancers.

### Conclusions

Since the initial discovery of *Lin28* and *let-7* by Ruvkun and Ambros 30 years ago, we are closer to understanding the full spectrum of mammalian functions for this heterochronic pathway. Furthermore, these studies on *Lin28* and *let-7* have provided insights into the possible phenotypic outputs of post-transcriptional regulation. We have only recently identified their novel roles in metabolic regulation and great strides have been made in understanding how this translates to organismal homeostasis, regeneration, and disease. There are still many open questions. Do *Lin28*-expressing tumors

have a distinctive metabolic signature when compared to those that are *Lin28*-negative? If *Lin28* does promote the Warburg effect, what impact do these effects have on tumor initiation versus progression? If *let-7* is to be used as an anti-cancer agent to target *Lin28*-positive tumors, will it alone be able to reverse the metabolic reprogramming events caused by *Lin28*? Since *Lin28* interacts and enhances translation of thousands of genes, would targeting a subset of these genes be sufficient to abrogate *Lin28*'s oncogenic effects? We hope that future studies on *Lin28* and *let-7* can shed light on some of these questions.

### Acknowledgements

**Funding:** LH Nguyen is supported by the International Pre-doctoral Fellowship from the Howard Hughes Medical Institute, H Zhu is supported by the Pollack Foundation, a NIH K08 grant (1K08CA157727), a Burroughs Wellcome Career Medical Award, and a *Cancer Prevention and Research Institute of Texas* New Investigator grant.

### Footnote

**Conflicts of Interest:** The authors have no conflicts of interest to declare.

### References

- Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. *Nat Rev Cancer* 2011;11:85-95.
- Warburg O. On the origin of cancer cells. *Science* 1956;123:309-14.
- Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. *Curr Opin Genet Dev* 2010;20:87-90.
- DeBerardinis RJ, Lum JJ, Hatzivassiliou G, et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. *Cell Metab* 2008;7:11-20.
- Shyh-Chang N, Daley GQ. *Lin28*: primal regulator of growth and metabolism in stem cells. *Cell Stem Cell* 2013;12:395-406.
- Zhu H, Shyh-Chang N, Segrè AV, et al. The *Lin28/let-7* axis regulates glucose metabolism. *Cell* 2011;147:81-94.
- Shyh-Chang N, Zhu H, Yvanka de Soysa T, et al. *Lin28* enhances tissue repair by reprogramming cellular metabolism. *Cell* 2013;155:778-92.
- Frost RJ, Olson EN. Control of glucose homeostasis and insulin sensitivity by the *Let-7* family of microRNAs. *Proc Natl Acad Sci U S A* 2011;108:21075-80.
- Molenaar JJ, Domingo-Fernández R, Ebus ME, et al. *LIN28B* induces neuroblastoma and enhances *MYCN* levels via *let-7* suppression. *Nat Genet* 2012;44:1199-206.
- Urbach A, Yermalovich A, Zhang J, et al. *Lin28* sustains early renal progenitors and induces Wilms tumor. *Genes Dev* 2014;28:971-82.
- King CE, Cuatrecasas M, Castells A, et al. *LIN28B* promotes colon cancer progression and metastasis. *Cancer Res* 2011;71:4260-8.
- Nguyen LH, Robinton DA, Seligson MT, et al. *Lin28b* is sufficient to drive liver cancer and necessary for its maintenance in murine models. *Cancer Cell* 2014;26:248-61.
- Viswanathan SR, Powers JT, Einhorn W, et al. *Lin28* promotes transformation and is associated with advanced human malignancies. *Nat Genet* 2009;41:843-8.
- Ambros V, Horvitz HR. Heterochronic mutants of the nematode *Caenorhabditis elegans*. *Science* 1984;226:409-16.
- Horvitz HR, Sulston JE. Isolation and genetic characterization of cell-lineage mutants of the nematode *Caenorhabditis elegans*. *Genetics* 1980;96:435-54.
- Moss EG, Lee RC, Ambros V. The cold shock domain protein *LIN-28* controls developmental timing in *C. elegans* and is regulated by the *lin-4* RNA. *Cell* 1997;88:637-46.
- Thummel CS. Molecular mechanisms of developmental timing in *C. elegans* and *Drosophila*. *Dev Cell* 2001;1:453-65.
- Moss EG, Tang L. Conservation of the heterochronic regulator *Lin-28*, its developmental expression and microRNA complementary sites. *Dev Biol* 2003;258:432-42.
- Abbott AL, Alvarez-Saavedra E, Miska EA, et al. The *let-7* MicroRNA family members *mir-48*, *mir-84*, and *mir-241* function together to regulate developmental timing in *Caenorhabditis elegans*. *Dev Cell* 2005;9:403-14.
- Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide *let-7* RNA regulates developmental timing in *Caenorhabditis elegans*. *Nature* 2000;403:901-6.
- Yang DH, Moss EG. Temporally regulated expression of *Lin-28* in diverse tissues of the developing mouse. *Gene Expr Patterns* 2003;3:719-26.
- Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. *Science* 2007;318:1917-20.
- Kim SK, Lee H, Han K, et al. *SET7/9* methylation of the pluripotency factor *LIN28A* is a nucleolar localization mechanism that blocks *let-7* biogenesis in human ESCs. *Cell Stem Cell* 2014;15:735-49.
- Van Wynsberghe PM, Kai ZS, Massirer KB, et al. *LIN-*

- 28 co-transcriptionally binds primary let-7 to regulate miRNA maturation in *Caenorhabditis elegans*. *Nat Struct Mol Biol* 2011;18:302-8.
25. Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of microRNA processing by Lin28. *Science* 2008;320:97-100.
  26. Rybak A, Fuchs H, Smirnova L, et al. A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. *Nat Cell Biol* 2008;10:987-93.
  27. Heo I, Joo C, Cho J, et al. Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA. *Mol Cell* 2008;32:276-84.
  28. Newman MA, Thomson JM, Hammond SM. Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. *RNA* 2008;14:1539-49.
  29. Lehrbach NJ, Armisen J, Lightfoot HL, et al. LIN-28 and the poly(U) polymerase PUP-2 regulate let-7 microRNA processing in *Caenorhabditis elegans*. *Nat Struct Mol Biol* 2009;16:1016-20.
  30. Nam Y, Chen C, Gregory RI, et al. Molecular basis for interaction of let-7 microRNAs with Lin28. *Cell* 2011;147:1080-91.
  31. Hagan JP, Piskounova E, Gregory RI. Lin28 recruits the TUTase Zcchc11 to inhibit let-7 maturation in mouse embryonic stem cells. *Nat Struct Mol Biol* 2009;16:1021-5.
  32. Piskounova E, Polytaichou C, Thornton JE, et al. Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. *Cell* 2011;147:1066-79.
  33. Copley MR, Babovic S, Benz C, et al. The Lin28b-let-7-Hmga2 axis determines the higher self-renewal potential of fetal haematopoietic stem cells. *Nat Cell Biol* 2013;15:916-25.
  34. Chang HM, Triboulet R, Thornton JE, et al. A role for the Perlman syndrome exonuclease Dis3l2 in the Lin28-let-7 pathway. *Nature* 2013;497:244-8.
  35. Thornton JE, Chang HM, Piskounova E, et al. Lin28-mediated control of let-7 microRNA expression by alternative TUTases Zcchc11 (TUT4) and Zcchc6 (TUT7). *RNA* 2012;18:1875-85.
  36. Melton C, Judson RL, Blelloch R. Opposing microRNA families regulate self-renewal in mouse embryonic stem cells. *Nature* 2010;463:621-6.
  37. Worringer KA, Rand TA, Hayashi Y, et al. The let-7/LIN-41 pathway regulates reprogramming to human induced pluripotent stem cells by controlling expression of prodifferentiation genes. *Cell Stem Cell* 2014;14:40-52.
  38. Lagos-Quintana M, Rauhut R, Yalcin A, et al. Identification of tissue-specific microRNAs from mouse. *Curr Biol* 2002;12:735-9.
  39. Inamura K, Togashi Y, Nomura K, et al. let-7 microRNA expression is reduced in bronchioloalveolar carcinoma, a non-invasive carcinoma, and is not correlated with prognosis. *Lung Cancer* 2007;58:392-6.
  40. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. *Cancer Res* 2004;64:3753-6.
  41. Gramantieri L, Ferracin M, Fornari F, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. *Cancer Res* 2007;67:6092-9.
  42. Shell S, Park SM, Radjabi AR, et al. Let-7 expression defines two differentiation stages of cancer. *Proc Natl Acad Sci U S A* 2007;104:11400-5.
  43. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. *Nature* 2005;435:834-8.
  44. Kumar MS, Lu J, Mercer KL, et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis. *Nat Genet* 2007;39:673-7.
  45. Johnson CD, Esquela-Kerscher A, Stefani G, et al. The let-7 microRNA represses cell proliferation pathways in human cells. *Cancer Res* 2007;67:7713-22.
  46. Schultz J, Lorenz P, Gross G, et al. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. *Cell Res* 2008;18:549-57.
  47. Dong Q, Meng P, Wang T, et al. MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. *PLoS One* 2010;5:e10147.
  48. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. *Genes Dev* 2007;21:1025-30.
  49. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. *Science* 2007;315:1576-9.
  50. Kasinski AL, Kelnar K, Stahlhut C, et al. A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. *Oncogene* 2014. [Epub ahead of print].
  51. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. *Cell* 2005;120:635-47.
  52. Esquela-Kerscher A, Trang P, Wiggins JE, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. *Cell Cycle* 2008;7:759-64.

53. Sampson VB, Rong NH, Han J, et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. *Cancer Res* 2007;67:9762-70.
54. He G, Dhar D, Nakagawa H, et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. *Cell* 2013;155:384-96.
55. Wilbert ML, Huelga SC, Kapeli K, et al. LIN28 binds messenger RNAs at GGAGA motifs and regulates splicing factor abundance. *Mol Cell* 2012;48:195-206.
56. Peng S, Chen LL, Lei XX, et al. Genome-wide studies reveal that Lin28 enhances the translation of genes important for growth and survival of human embryonic stem cells. *Stem Cells* 2011;29:496-504.
57. Polesskaya A, Cuvellier S, Naguibneva I, et al. Lin-28 binds IGF-2 mRNA and participates in skeletal myogenesis by increasing translation efficiency. *Genes Dev* 2007;21:1125-38.
58. Janiszewska M, Suvà ML, Riggi N, et al. Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. *Genes Dev* 2012;26:1926-44.
59. Hafner M, Max KE, Bandaru P, et al. Identification of mRNAs bound and regulated by human LIN28 proteins and molecular requirements for RNA recognition. *RNA* 2013;19:613-26.
60. Wang J, Alexander P, Wu L, et al. Dependence of mouse embryonic stem cells on threonine catabolism. *Science* 2009;325:435-9.
61. Shyh-Chang N, Locasale JW, Lyssiotis CA, et al. Influence of threonine metabolism on S-adenosylmethionine and histone methylation. *Science* 2013;339:222-6.
62. Zhu H, Shah S, Shyh-Chang N, et al. Lin28a transgenic mice manifest size and puberty phenotypes identified in human genetic association studies. *Nat Genet* 2010;42:626-30.
63. Lettre G, Jackson AU, Gieger C, et al. Identification of ten loci associated with height highlights new biological pathways in human growth. *Nat Genet* 2008;40:584-91.
64. Widén E, Ripatti S, Cousminer DL, et al. Distinct variants at LIN28B influence growth in height from birth to adulthood. *Am J Hum Genet* 2010;86:773-82.
65. Shinoda G, Shyh-Chang N, Soysa TY, et al. Fetal deficiency of lin28 programs life-long aberrations in growth and glucose metabolism. *Stem Cells* 2013;31:1563-73.
66. Trumpp A, Refaeli Y, Oskarsson T, et al. c-Myc regulates mammalian body size by controlling cell number but not cell size. *Nature* 2001;414:768-73.
67. Weedon MN, Lettre G, Freathy RM, et al. A common variant of HMGA2 is associated with adult and childhood height in the general population. *Nat Genet* 2007;39:1245-50.
68. Christiansen J, Kolte AM, Hansen Tv, et al. IGF2 mRNA-binding protein 2: biological function and putative role in type 2 diabetes. *J Mol Endocrinol* 2009;43:187-95.
69. Dubinsky AN, Dastidar SG, Hsu CL, et al. Let-7 coordinately suppresses components of the amino acid sensing pathway to repress mTORC1 and induce autophagy. *Cell Metab* 2014;20:626-38.
70. Ma X, Li C, Sun L, et al. Lin28/let-7 axis regulates aerobic glycolysis and cancer progression via PDK1. *Nat Commun* 2014;5:5212.
71. Kolobova E, Tuganova A, Boulatnikov I, et al. Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites. *Biochem J* 2001;358:69-77.

**Cite this article as:** Nguyen LH, Zhu H. Lin28 and *let-7* in cell metabolism and cancer. *Transl Pediatr* 2015;4(1):4-11. doi: 10.3978/j.issn.2224-4336.2015.01.05